ArticleCancer communications (London, England)2020
Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China.
Article in Cancer communications (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: a meta-analysis.Systematic reviews · 2025Pooled it
- Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.Frontiers in immunology · 2022Pooled it
- The Impact of Preoperative Sarcopenia on Survival Prognosis in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial.Nature communications · 2025Trial
- Iodine Staining With Distance Countdown Improving the Safety for Reduction of Adverse Events: A Randomized Controlled Trial.Clinical and translational gastroenterology · 2025Trial
- Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures.Radiation oncology (London, England) · 2022Trial
- Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes.Annals of medicine · 2026Article
- One-Lung Ventilation Duration Is a Risk Factor for Pneumonia in Minimally Invasive and Robotic Esophagectomy.Journal of clinical medicine · 2026Article
- Long-term trends in disease burden of esophageal cancer in China and the forecast until 2050.BMC gastroenterology · 2026Article
- ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1-Mediated Lipid Metabolic Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The White Plane in Esophageal Surgery: A Novel Anatomical Landmark with Prognostic Significance.Cancers · 2025Article
- A computed tomography-based deep learning radiomics for predicting the response to neoadjuvant chemotherapy combined with immunotherapy in patients with locally advanced esophageal cancer: a multicenter cohort study.Journal of thoracic disease · 2025Article
- Emerging non-invasive imaging biomarkers of Ki-67 in pancreatic cancer: Toward predictive precision oncology.World journal of gastrointestinal oncology · 2025Article
- Radiomics meets sarcopenia: Machine learning-based multimodal modeling for esophageal cancer outcomes.World journal of gastrointestinal oncology · 2025Review
- A novel prognostic nomogram to predict survival of patients with esophageal squamous cell carcinoma after definitive chemoradiotherapy.Journal of thoracic disease · 2025Article
- Analysis of mortality trends and projected burden of digestive system cancer in China: a nationwide longitudinal analysis (2006-2020) with mortality forecasts to 2045.Discover oncology · 2025Article
- Article
- CT-radiomics combined with inflammatory indicators for prediction of progression free survival of resectable esophageal squamous cell carcinoma.Scientific reports · 2025Article
- Perioperative risk factors for prognosis in patients undergoing radical esophagectomy: A retrospective study.World journal of gastrointestinal surgery · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the potential determining epidemiological and clinical risk factors affecting the survival of esophageal cancer (EC) patients across multiple hospitals in China.
methodsThis was a multicenter study comprising of newly diagnosed EC cases from Beijing, Hebei, Henan, Hubei, Zhejiang, and Guangdong Province of China. Their baseline characteristics and treatment methods data were collected from their medical records. The EpiData software was used for data quality control. The Kaplan-Meier method was used to estimate their overall survival (OS), and the Cox's proportional hazard regression model was used to estimate hazard ratios (HR) and 95% confidence interval (CI).
resultsThe 3- and 5-year OS rates of the 5283 investigated EC patients were 49.98% and 39.07%, respectively. Their median survival was 36.00 months. The median survival time of females was longer than that of males (females vs. males: 45.00 vs. 33.00, P < 0.001). The 5-year OS rate of patients who never-smoked was higher than that of smokers (never-smokers vs smokers: 40.73% vs. 37.84%, P = 0.001). There was no significant difference in the 5-year OS rate between drinkers and never-drinkers (drinkers vs never-drinkers: 34.22% vs. 29.65%, P = 0.330). In multivariate analysis, pathological stage (stage II: HR = 1.80, 95% CI = 1.40-2.31; stage III: HR = 2.62, 95% CI = 2.06-3.34; stage IV: HR = 3.90, 95% CI = 2.98-5.09), poor differentiation/undifferentiated (HR = 1.34, 95% CI = 1.11-1.63), not married status (HR = 2.45, 95% CI = 1.49-4.04), production and service personnel (HR = 1.36, 95% CI = 1.01-1.83) and farming/fishing (HR = 1.40, 95% CI = 1.12-1.76) were independent prognostic risk factors for poor EC survival. Tumors in the thoracic or abdominal part of the esophagus, female and family history of any cancer were independent factors predictive of a good EC OS.
conclusionGender, marital status, occupation, family history of any cancer, tumor topographical site, differentiation status, and pathological stage were associated with the survival rate of EC. This study reveals important clinical characteristics of esophageal cancer patients in China and provides helpful information for their clinical management and surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.